Literature DB >> 8815313

Characterization of antibodies to nerve growth factor: assay-dependent variability in the cross-reactivity with other neurotrophins.

J M Conner1, S Varon.   

Abstract

The neurotrophin family of growth factors consists of proteins sharing a sizable degree of amino acid sequence and structural homology. These similarities greatly increase the probability that antibodies directed against any single neurotrophin may cross-react with other family-members. Various investigators have documented such cross-reactivity can occur under experimental conditions, although the extent of cross-reactivity reported in different studies has varied greatly. Although the use of different antibody preparations may have contributed to the differing degrees of cross-reactivity observed, it is important to note that different assay conditions were also used to evaluate cross-reactivity in the various studies. Little information is currently known about how antibody-antigen interactions vary as a function of the assay conditions used for the evaluation. The present study addressed this question by evaluating the cross-reactivity occurring between various neurotrophins and a single preparation of antibodies directed against purified mouse nerve growth factor-beta (beta-NGF) in a wide variety of immunological assay systems. Our results indicate that cross-reactivity between NGF antibodies and related neurotrophins can vary greatly depending upon the assay system chosen for the evaluation. These data strongly argue against transferring cross-reactivity data across various assay systems.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8815313     DOI: 10.1016/0165-0270(95)00151-4

Source DB:  PubMed          Journal:  J Neurosci Methods        ISSN: 0165-0270            Impact factor:   2.390


  8 in total

1.  Nontropic actions of neurotrophins: subcortical nerve growth factor gene delivery reverses age-related degeneration of primate cortical cholinergic innervation.

Authors:  J M Conner; M A Darracq; J Roberts; M H Tuszynski
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

2.  Local and remote growth factor effects after primate spinal cord injury.

Authors:  John H Brock; Ephron S Rosenzweig; Armin Blesch; Rod Moseanko; Leif A Havton; V Reggie Edgerton; Mark H Tuszynski
Journal:  J Neurosci       Date:  2010-07-21       Impact factor: 6.167

3.  Nerve Growth Factor Gene Therapy: Activation of Neuronal Responses in Alzheimer Disease.

Authors:  Mark H Tuszynski; Jennifer H Yang; David Barba; Hoi-Sang U; Roy A E Bakay; Mary M Pay; Eliezer Masliah; James M Conner; Peter Kobalka; Subhojit Roy; Alan H Nagahara
Journal:  JAMA Neurol       Date:  2015-10       Impact factor: 18.302

4.  Bone Marrow Stromal Cell Intraspinal Transplants Fail to Improve Motor Outcomes in a Severe Model of Spinal Cord Injury.

Authors:  John H Brock; Lori Graham; Eileen Staufenberg; Eileen Collyer; Jacob Koffler; Mark H Tuszynski
Journal:  J Neurotrauma       Date:  2015-11-13       Impact factor: 5.269

5.  Long-term reversal of cholinergic neuronal decline in aged non-human primates by lentiviral NGF gene delivery.

Authors:  Alan H Nagahara; Tim Bernot; Rod Moseanko; Laurie Brignolo; Armin Blesch; James M Conner; Anthony Ramirez; Mehdi Gasmi; Mark H Tuszynski
Journal:  Exp Neurol       Date:  2008-10-25       Impact factor: 5.330

6.  Nerve growth factor is primarily produced by GABAergic neurons of the adult rat cortex.

Authors:  Jeremy Biane; James M Conner; Mark H Tuszynski
Journal:  Front Cell Neurosci       Date:  2014-08-07       Impact factor: 5.505

7.  LncRNA HOTAIR regulates glucose transporter Glut1 expression and glucose uptake in macrophages during inflammation.

Authors:  Monira Obaid; S M Nashir Udden; Prasanna Alluri; Subhrangsu S Mandal
Journal:  Sci Rep       Date:  2021-01-08       Impact factor: 4.996

8.  NGF is essential for hippocampal plasticity and learning.

Authors:  James M Conner; Kevin M Franks; Andrea K Titterness; Kyle Russell; David A Merrill; Brian R Christie; Terrence J Sejnowski; Mark H Tuszynski
Journal:  J Neurosci       Date:  2009-09-02       Impact factor: 6.167

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.